HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has announced a conference call scheduled for August 13 at 4:30 p.m. ET to review its second-quarter financial results for the period ended June 30, 2026, and provide strategic updates aimed at accelerating global adoption of its ambulatory ECG signal platform. The call will be led by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank, and will include a question-and-answer session following prepared remarks.
This announcement underscores the company's progress following significant regulatory milestones. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The platform is the first cable-free device capable of collecting ECG signals in three non-coplanar directions and synthesizing them into a 12-lead ECG, designed for portable use outside medical facilities. This capability allows physicians to identify cardiac health trends and acute conditions, directing patients to appropriate care remotely.
The upcoming call comes as HeartBeam holds over 20 issued patents related to its technology, positioning it to redefine cardiac health management. The company's strategy focuses on driving adoption of its platform, which aims to deliver actionable heart intelligence wherever the patient is. The financial results and strategy update will be closely watched by investors and healthcare stakeholders, as the company seeks to capitalize on its FDA clearances and expand its market presence.
For more details, the full press release is available at https://ibn.fm/sqGLs. Additional information about HeartBeam and its cleared indications for use can be found at https://www.heartbeam.com/indications. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
